The Federal Trade Commission, along with Alaska, Iowa, Nebraska, and Texas, filed a lawsuit against the World Professional Association for Transgender Health (WPATH) on June 17, 2026, alleging the organization provided guidance that enabled medical providers to make false and unsubstantiated claims to parents about pediatric medical transition services. This action represents a significant enforcement effort against health claims in the wellness and medical sectors, highlighting how regulatory agencies are scrutinizing organizations that influence clinical practice and consumer decision-making.

What Claims Did WPATH Make That Triggered the Lawsuit?

According to the complaint, WPATH recommended medical interventions, including puberty blockers, cross-sex hormones, and surgical procedures, for children and adolescents experiencing distress about their sex traits. The FTC and state partners allege that WPATH's recommendations misled parents and children about the medical consensus, medical necessity, and safety and effectiveness of these services.

One particularly concerning allegation involves how clinicians, relying on WPATH guidance, presented these interventions to families. The complaint describes instances where parents were asked whether they "would rather have a live daughter or a dead son," based on WPATH's representation that pediatric medical transition services are "lifesaving." However, the FTC argues there is no competent and reliable scientific evidence to suggest these interventions reduce the risk of suicide.

What Specific Safety Information Did WPATH Allegedly Fail to Disclose?

The lawsuit highlights significant gaps in how WPATH communicated potential side effects to families and medical professionals. According to the complaint, WPATH failed to disclose serious adverse effects associated with cross-sex hormones, including:

• Mood Changes: Cross-sex hormones can cause mood disturbances that may affect mental health and daily functioning.
• Reproductive and Sexual Effects: Patients may experience pelvic pain, clitoral discomfort, vaginal pain, inability to orgasm, incontinence, and erectile pain.
• Voice and Pain Issues: Some patients reported vocal pain and limitations that could affect communication and quality of life.

The FTC argues that withholding this information prevented parents and children from making fully informed decisions about irreversible medical interventions.

How Did WPATH's Guidelines Influence Medical Practice?

WPATH claims its recommendations represent "consensus-based expert opinion," but the FTC alleges this framing led WPATH members and other clinicians to repeat false, misleading, or unsubstantiated statements about safety and efficacy to consumers. Additionally, the complaint asserts that despite lacking competent and reliable scientific evidence, WPATH's guidelines labeled nearly every pediatric transition service as "medically necessary" to maximize the likelihood that insurers would pay for these procedures.

This practice is particularly significant because it demonstrates how organizational guidance can shape clinical messaging and influence insurance coverage decisions, ultimately affecting access to and uptake of these services among vulnerable populations.

What Changes Did WPATH Make Without Scientific Justification?

In 2022, WPATH removed all mention of age limitations for breast amputation or penis removal from its "Standards of Care" document. The FTC alleges that WPATH did not base this decision on medical evidence, raising questions about whether the change was driven by ideology rather than scientific findings.

"Children, but especially their parents, must have complete and truthful information when making decisions to purchase medical services. For decades, the FTC has taken action against entities that make deceptive and unsubstantiated health-related claims. The complaint filed today reflects that same long-standing mandate: when an entity makes a claim about a medical treatment, the claim must be truthful, evidence-based and not misleading," said FTC Chairman Andrew N. Ferguson.

Andrew N. Ferguson, Chairman, Federal Trade Commission

How to Evaluate Health Claims From Medical Organizations?

This lawsuit underscores the importance of critical evaluation when reviewing guidance from medical organizations, especially when those recommendations influence irreversible treatments. Consumers and families should consider the following steps:

• Verify Scientific Evidence: Ask whether claims are supported by peer-reviewed research, not just organizational consensus or expert opinion. Request specific studies and data rather than accepting assertions at face value.
• Demand Full Disclosure of Side Effects: Legitimate medical guidance should transparently list all known adverse effects, including rare but serious ones. If an organization downplays or omits side effects, that is a red flag.
• Seek Independent Medical Opinions: For major medical decisions, especially those involving irreversible procedures, consult multiple independent clinicians who are not affiliated with the organization making the recommendation.
• Question Financial Incentives: Consider whether the organization or clinicians profit from recommending a particular treatment, which could create bias toward promoting that treatment regardless of evidence.

The FTC's action reflects broader concerns about how health organizations communicate with consumers and influence clinical practice. Commissioner Mark R. Meador emphasized this point, noting that when organizations provide guidance designed to mislead families about risks, benefits, or medical consensus, it undermines trust in healthcare providers.

The lawsuit was filed in the U.S. District Court for the Northern District of Texas, and the case will ultimately be decided by the court. The FTC Commission voted 2-0 to authorize staff to file the complaint, indicating strong consensus within the agency about the seriousness of the allegations.

This enforcement action serves as a reminder that health and wellness organizations, regardless of their professional status or reputation, are subject to the same consumer protection laws that apply to other industries. When organizations make claims about medical treatments, those claims must be truthful, evidence-based, and not misleading, particularly when vulnerable populations like children are involved.